p53-Based cyclotherapy: exploiting the ‘guardian of the genome’ to protect normal cells from cytotoxic therapy
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/bjc2013702.pdf
Reference31 articles.
1. Agarwal ML, Agarwal A, Taylor WR, Stark GR (1995) p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92 (18): 8493–8497.
2. Blagosklonny MV (2002) Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 21 (41): 6249–6254.
3. Blagosklonny MV, Pardee AB (2001) Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 61 (11): 4301–4305.
4. Blagosklonny MV, Robey R, Bates S, Fojo T (2000) Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 105 (4): 533–539.
5. Brown CJ, Quah ST, Jong J, Goh AM, Chiam PC, Khoo KH, Choong ML, Lee MA, Yurlova L, Zolghadr K, Joseph TL, Verma CS, Lane DP (2013) Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol 8 (3): 506–512.
Cited by 55 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. GRK2-mediated AKT activation controls cell cycle progression and G2 checkpoint in a p53-dependent manner;Cell Death Discovery;2024-08-29
2. Understanding the complexity of p53 in a new era of tumor suppression;Cancer Cell;2024-06
3. GRK2-mediated AKT activation controls cell cycle progression and G2-checkpoint in a p53-dependent manner;2024-01-28
4. Actinomycin D synergizes with Doxorubicin in triple-negative breast cancer by inducing P53-dependent cell apoptosis;Carcinogenesis;2023-11-24
5. CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan;Cell Cycle;2023-06-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3